Specifically, we observed disparities in the prevalence of metachronous versus synchronous metastatic disease, as well as variations in the location-dependent metastatic sequence, Pn and V status, applications of systemic chemotherapy (CTX), and KRAS mutational status (Table 2). Here, KRAS is linked to metastatic neoplasm.